Skip to main content
Mayer Fishman, MD, Oncology, Tampa, FL

Mayer Fishman MD


Associate Professor of Medicine, University S Fla College of Medicine

Join to View Full Profile
  • 12902 Usf Magnolia Dr# GuTampa, FL 33612

  • Phone+1 813-745-8343

  • Fax+1 813-745-8494

Dr. Fishman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General Hospital
    University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1993 - 1996
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 1993

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1997 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Tampa General Hospital Improves Access to Cancer Care and Treatment in the Riverview Area
    Tampa General Hospital Improves Access to Cancer Care and Treatment in the Riverview AreaSeptember 17th, 2021
  • Combination Axitinib + Pembrolizumab Active Against Renal Cell Carcinoma
    Combination Axitinib + Pembrolizumab Active Against Renal Cell CarcinomaFebruary 16th, 2018
  • Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an on-Going Observational IL-2 Clinical Trial: PROCLAIM SM
    Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an on-Going Observational IL-2 Clinical Trial: PROCLAIM SMFebruary 1st, 2017
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: